ESC 365 - Emerging cardio-oncology therapeutics: the role of ivabradine and levosimendan in acute heart failure reversible toxicity

HFA Premium Access

Emerging cardio-oncology therapeutics: the role of ivabradine and levosimendan in acute heart failure reversible toxicity

Session: Poster Session 2 - Clinical Cases

Topic: Cardiotoxicity of Drugs and Other Therapies

Speaker: Doctor G. El-Khoury (Toronto, CA)

Event: Heart Failure 2019

Congress Presentation

Add to my library

About the speaker

Doctor Georges El-Khoury

University of Toronto, Toronto (Canada)

0 follower

34 more presentations in this session

Acute hypertensive heart failure - when the etiology is misleading

Speaker: Miss A. Burducea (Bucuresti, RO)

Wild type TTR amyloidosis disguised as concentric hypertensive left ventricular hypertrophy

Speaker: Doctor A. Siama (Maroussi-Athens, GR)

"Burned-out" hypertrophic obstructive cardiomyopathy presenting as acute coronary syndrome

Speaker: Doctor A. Kalogeris (Athens, GR)

Successful antiarrhythmic therapy with combination of quinidine and mexiletine in Purkinje-related ventricular arrhythmia, persistent atrial tachyarrhythmia and DCM associated with R814W SCN5Amutation

Speaker: Doctor J. Zakrzewska-Koperska (Warsaw, PL)

Clinical case of effective treatment of ventricular arrhythmias with ranolazine in a 32-year-old woman with unclear aetiology cardiac inflammation

Access the full session

Poster Session 2 - Clinical Cases

Speakers: Doctor G. El-Khoury, Miss A. Burducea, Doctor A. Siama, Doctor A. Kalogeris, Doctor J. Zakrzewska-Koperska

About the event

Heart Failure 2019

25 May - 28 May 2019

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources